New nucleoside analogues for chronic hepatitis B.
In recent years, an in vitro system for screening nucleoside analogues against hepatitis B virus has yielded several compounds with a high therapeutic index. Phase I and II studies have also shown a potent in vivo antiviral effect of fialuridine and lamivudine in patients with chronic hepatitis B. The use of fialuridine was associated with unexpectedly severe mitochondrial dysfunction; in contrast, lamivudine had virtually no side-effects. Experience in liver transplant patients with recurrent hepatitis B shows that famciclovir may be another effective antivirotic drug with good tolerance.
Schalm
S W
SW
Department of Internal Medicine II, (Hepatology Section), Erasmus University, Rotterdam, The Netherlands.
de Man
R A
RA
Heijtink
R A
RA
Niesters
H G
HG
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D002908:Chronic Disease; D004353:Drug Evaluation, Preclinical; D000077595:Famciclovir; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine; D009705:Nucleosides / Q000627:therapeutic use*; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000998:Antiviral Agents; D009705:Nucleosides; D019259:Lamivudine; D001086:Arabinofuranosyluracil; D015075:2-Aminopurine; C043457:fialuridine; D016047:Zalcitabine; D000077595:Famciclovir